Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Plamotamab · 1 trial · 1 indication
Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Plamotamab administered SC |
| Name | Type | Description |
|---|---|---|
| Plamotamab | BIOLOGICAL | Biological |
Inclusion Criteria: Adult participants with moderately to severely active RA. * Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening * Inadequate respon...
Top 20 of 28 competitors
Plamotamab is an investigational monoclonal antibody being studied for the treatment of rheumatoid arthritis. It is currently in Phase 1 clinical development, with an ongoing open-label trial evaluating its safety in participants with this condition.
Plamotamab is a monoclonal antibody, classified as a -mab (antibody) therapeutic. Its specific molecular target has not been disclosed in available information, so the precise mechanism of action is not detailed.
Plamotamab is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XNCR. The company is conducting a Phase 1 clinical trial for this drug in rheumatoid arthritis.
Plamotamab is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The current trial is a Phase 1b open-label study focused on evaluating safety in participants with rheumatoid arthritis.
Plamotamab is being studied in a single active clinical trial, identified as NCT07230353. This is a Phase 1b open-label study titled 'A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis,' which is currently recruiting participants.
Plamotamab is a distinct investigational monoclonal antibody developed by Xencor, Inc. No alternative names for this drug have been reported in available clinical trial information, so it is not known to be identical to any other approved or investigational therapy.